Intercytex turns to Vavelta and cuts staff
This article was originally published in Scrip
Executive Summary
Intercytex will focus on developing Vavelta after the disappointing Phase III results of its lead wound care candidate Cyzact (ICX-PRO). It is cutting 26 jobs, shrinking its workforce from 76 to 50, as part of a restructuring programme announced in January to eventually reduce the headcount by half and reduce its cash burn.